GENCYTE THERAPEUTICS INC
SBIR Phase I award from Department of Health and Human Services.
Summary
Gencyte Therapeutics Inc. received nearly $500,000 from NIH for a Phase I SBIR project to develop a logic-gated molecular adaptor system. The goal is early-stage research on a targeted therapy for JMML, a rare childhood blood cancer.
- Amount
- $499,990
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CA
- Period
- 2025-09-12 → 2026-09-11
Technology domains
Human Performance & Medical
Description
PHASE I SBIR CONCEPT AWARD FOR LOGIC GATED MOLECULAR ADAPTOR SYSTEM FOR JMML TREATMENT